Three patients with a rare blistering skin disease reported faster healing and less pain using topical CBD oil
Three patients with epidermolysis bullosa who self-initiated topical CBD oil reported faster wound healing, less blistering, and reduced pain, with one patient completely weaning off oral opioid painkillers.
Quick Facts
What This Study Found
Epidermolysis bullosa (EB) is a rare genetic blistering skin disorder that causes chronic wounds, pain, and limited mobility with few effective treatments. Three patients with EB independently began using topical CBD oil and were observed in this case series.
All three patients reported meaningful improvements: faster wound healing, less blistering, and significant pain reduction. The most dramatic case was a patient who was completely weaned off oral opioid analgesics after starting topical CBD. The other two patients also experienced meaningful pain relief.
The patients attributed the benefits to CBD's proposed anti-inflammatory and analgesic properties. The topical application allowed direct delivery to affected skin areas, potentially achieving therapeutic concentrations locally without significant systemic effects.
Key Numbers
3 patients with epidermolysis bullosa. All 3 reported faster wound healing, less blistering, and pain improvement. 1 patient completely weaned off oral opioid analgesics.
How They Did This
This was an observational case series of 3 patients with epidermolysis bullosa who self-initiated topical CBD oil use. Clinical observations of wound healing, blistering frequency, and pain levels were documented.
Why This Research Matters
Epidermolysis bullosa has very limited treatment options, and patients live with chronic pain that often requires opioids. If topical CBD can reduce pain and improve wound healing in this population, it would represent a significant advance for a condition that affects quality of life severely from birth.
The Bigger Picture
This case series sits at the intersection of rare disease treatment and cannabinoid medicine. While the evidence is very preliminary, the consistent response across three patients with a well-defined condition that lacks good treatments makes this a compelling signal for further investigation.
What This Study Doesn't Tell Us
Only 3 patients were observed, with no control group, blinding, or standardized outcome measures. Patients self-initiated CBD use, introducing potential placebo effects and reporting bias. The specific CBD products, concentrations, and application protocols were not standardized. The observational design cannot establish causation.
Questions This Raises
- ?Would a randomized controlled trial confirm these observations?
- ?What is the optimal CBD concentration and formulation for topical wound treatment?
- ?Could topical CBD benefit other chronic wound conditions beyond epidermolysis bullosa?
Trust & Context
- Key Stat:
- One patient completely weaned off opioid painkillers with topical CBD
- Evidence Grade:
- This is a 3-patient case series with no controls, providing preliminary evidence that warrants further investigation.
- Study Age:
- Published in 2018. Research on topical CBD for wound healing has continued.
- Original Title:
- Self-initiated use of topical cannabidiol oil for epidermolysis bullosa.
- Published In:
- Pediatric dermatology, 35(4), e224-e227 (2018)
- Authors:
- Chelliah, Malcolm P, Zinn, Zachary, Khuu, Phoung, Teng, Joyce M C
- Database ID:
- RTHC-01619
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
Can CBD help with skin wounds?
These three case reports suggest topical CBD may promote wound healing and reduce pain in epidermolysis bullosa, a rare blistering skin condition. One patient was able to stop opioid painkillers entirely. However, this is very early evidence from only three patients without controls.
How was the CBD applied?
Patients applied CBD oil directly to affected skin areas. The topical route allows the compound to reach wound sites directly. The specific products and concentrations were not standardized as patients self-selected their CBD oils.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01619APA
Chelliah, Malcolm P; Zinn, Zachary; Khuu, Phoung; Teng, Joyce M C. (2018). Self-initiated use of topical cannabidiol oil for epidermolysis bullosa.. Pediatric dermatology, 35(4), e224-e227. https://doi.org/10.1111/pde.13545
MLA
Chelliah, Malcolm P, et al. "Self-initiated use of topical cannabidiol oil for epidermolysis bullosa.." Pediatric dermatology, 2018. https://doi.org/10.1111/pde.13545
RethinkTHC
RethinkTHC Research Database. "Self-initiated use of topical cannabidiol oil for epidermoly..." RTHC-01619. Retrieved from https://rethinkthc.com/research/chelliah-2018-selfinitiated-use-of-topical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.